Our Expert in Spain
No results available
Change of control consents spain are among the most underestimated execution risks in cross‑border acquisitions of Spanish tech and life‑sciences targets, and in 2026 they sit at the intersection of private contract law, tightened foreign direct investment (FDI) screening and sector‑specific regulatory approvals. This guide sets out a practical, step‑by‑step workflow for identifying, securing and remediating those consents, written for in‑house counsel, private equity sponsors and deal lawyers who need a realistic action plan rather than high‑level commentary. It combines contract triage, a sample timetable with owner responsibilities, an FDI screening checklist and fallback drafting options, with every procedural claim traceable to primary Spanish and EU sources.
The emphasis throughout is on tech and life‑sciences deals, where IP licences, SaaS arrangements, marketing authorisations and clinical trial agreements concentrate consent exposure. Read it as an operational playbook to deploy from the first day of diligence through to post‑closing novation filings.
This guide addresses one discrete but deal‑critical workstream: securing the third‑party and regulatory approvals that a Spanish target’s contracts and licences require when control changes hands. It is deliberately procedural. It tells you who owns each task, how long each stage realistically takes, what documents you need, and what to do when a counterparty says no.
Where a contract contains a change‑of‑control clause, closing a deal without the required consent can trigger termination rights, acceleration, penalty payments or loss of a licence. In tech and life‑sciences targets, a single refused consent, a core software licence, an anchor customer contract or a marketing authorisation, can strip material value from the business the buyer thought it was acquiring. Change of control consents spain therefore need to be managed as a dedicated condition‑to‑closing workstream, not an afterthought bundled into general diligence.
These sectors carry disproportionate consent density: IP and SaaS licences, distribution and reseller agreements, clinical trial and manufacturing contracts, and data processing arrangements. They also attract heightened FDI scrutiny under both the EU framework and the Spanish regime, making change‑of‑control approvals spain a combined contractual and regulatory exercise.
Consent exposure depends on both deal structure and the specific portfolio of contracts and licences. A share sale leaves the target company party to its contracts but triggers any change‑of‑control clause; an asset or business transfer instead raises assignment and novation questions for every material contract. Understanding which contracts trigger consents is the foundation of the whole workstream.
The following categories most commonly contain change‑of‑control or anti‑assignment provisions in Spanish tech and life‑sciences targets and should be prioritised in any triage of third‑party consents Spain:
The governing private‑law backdrop is the Spanish Civil Code (Código Civil), which sets the framework for contractual obligations, consent and assignment of rights and duties. Under general Spanish contract‑law principles, the assignment of a party’s obligations typically requires the counterparty’s consent, whereas the assignment of rights may in some cases be effected without it; the terms of each contract and the applicable Civil Code provisions determine whether counterparty consent is legally required where a contract is silent.
Beyond private contracts, a cluster of statutory and sectoral approvals may apply to change‑of‑control approvals Spain:
If the target holds public contracts, assignment and novation are governed by Spanish public procurement legislation, principally Law 9/2017 on Public Sector Contracts (Ley de Contratos del Sector Público). Public contract novation Spain is materially more rigid than private consent: transfer typically requires contracting‑authority approval and compliance with statutory assignment conditions, and in some cases cannot be achieved without jeopardising the contract. Identify public contracts early, because they can dictate deal structure.
Success in this workstream looks like this: every material consent trigger identified before signing, a sequenced plan allocating each notice and filing to a named owner, counterparty and regulatory responses obtained (or risk‑allocated through drafting) by closing, and clean post‑closing records. The seven steps below map directly to that outcome.
Step 1, Pre‑sale consent audit (Vendor, with external counsel). The vendor legal team extracts the full contract archive and runs a structured triage. Work through three sub‑steps: (i) contract extraction, assemble every material agreement, licence and public contract; (ii) red‑flag mapping, identify each change‑of‑control, anti‑assignment, notice and termination clause; and (iii) prioritisation, rank each trigger high, medium or low by deal impact. A high‑priority trigger is one whose loss materially affects value or whose counterparty has an obvious incentive to extract concessions. Capture notice periods and response windows in a contract summary table so the drafting team can move quickly. Estimated duration: 1–2 weeks. Required docs: full contract archive, contract summary table.
Step 2, Consent strategy and sequencing (Buyer, seller and lead counsel). Decide, contract by contract, whether the clause requires a consent request or only a notice, and whether a temporary waiver or standstill is achievable. Sequence filings so that long‑lead regulatory items (notably FDI) start in parallel with contractual outreach. Agree who approaches each counterparty, a seller‑led approach preserves the relationship and limits information leakage, while a buyer‑led approach may be necessary where the counterparty wants to assess the new owner. Decide how to allocate unresolved consent risk between escrow, holdback, warranty and indemnity (W&I) cover and specific indemnities. Estimated duration: 3–5 days. Required docs: prioritisation / red‑flag report.
Step 3, Drafting notice and engagement materials (Seller and counsel). Standardise a consent request pack: a notice letter, a confidentiality cover memo and a short transaction summary. A well‑drafted consent notice should state who is requesting consent, summarise the transaction, list the enclosed documents, specify a clear response deadline and name a contact person. Standardisation sharply reduces follow‑up correspondence and shortens the response window. Use the sample template below as a baseline. Estimated duration: 3–7 days. Required docs: draft consent notice, cover letter, transaction summary.
Step 4, Filing and regulatory notifications (Buyer, or as required). Submit statutory filings in parallel with contractual outreach. Where the Spanish FDI regime applies, prepare and lodge the FDI pack; where thresholds are met, prepare the CNMC merger notification; and where life‑sciences authorisations are in scope, engage AEMPS on any transfer of marketing authorisations. For public contracts, open early dialogue with the contracting authority on novation. These regulatory clocks are statutory and cannot be compressed by commercial pressure, so start them first. Estimated duration: 2–12+ weeks depending on the regime. Required docs: regulatory filings and cover notes.
Step 5, Negotiation and remediation (Deal counsel and counterparties). Where a counterparty hesitates or seeks concessions, deploy the agreed levers: a buy‑side holdback, W&I cover or a specific indemnity for the identified contract. For hard‑to‑get consents, consider offering security or undertakings (for example, a parent guarantee or performance assurance). Track consent leakage Spain, the gradual erosion of value as counterparties extract price reductions, extended terms or new obligations in exchange for consent, and set internal limits on what the deal can absorb. Estimated duration: 1–6 weeks. Required docs: evidence of security/undertakings, transaction documents.
Step 6, Closing mechanics and post‑closing novation / assignment steps (Both parties). Align obtained consents with the closing condition schedule. Where certain consents cannot be obtained before closing, structure them as post‑closing covenants with defined long‑stop dates and consequences. For asset or business transfers, prepare the novation and assignment documentation so it can be executed in the agreed sequence. Estimated duration: align with the agreed closing date. Required docs: transaction documents, authorised signatory evidence.
Step 7, Post‑close confirmatory actions and record keeping (Buyer / seller). After closing, complete outstanding novation and assignment filings, register IP transfers where required, confirm regulatory conditions are satisfied and assemble a complete consent register evidencing every approval. Clean records protect the buyer in any later dispute and support the next transaction. Estimated duration: 1–6 weeks post‑close. Required docs: proof of filings, consent register.
The following is a baseline template reflecting common practice. Adapt the wording to each contract and have a Spain‑qualified practitioner review it before use; it is not a substitute for specific legal advice.
English: “Dear [Counterparty], We write in connection with [Agreement, dated]. We hereby notify you that [Target] is subject to a proposed change of control arising from [transaction summary]. Under clause [X] of the Agreement your consent is [required / requested]. Enclosed are [list of documents]. We should be grateful to receive your written consent by [date, typically two to four weeks]. Please direct any questions to [contact].”
Spanish (suggested): “Estimado/a [Contraparte]: Nos dirigimos a usted en relación con [el Contrato, de fecha]. Por la presente le notificamos que [la Sociedad] será objeto de un cambio de control derivado de [resumen de la operación]. De conformidad con la cláusula [X] del Contrato, su consentimiento es [necesario / solicitado]. Se adjuntan [relación de documentos]. Le agradeceríamos que nos remitiera su consentimiento por escrito antes del [fecha]. Para cualquier consulta, diríjase a [contacto].”
The documents below should be gathered and kept current throughout the process. Assembling them early is the single biggest accelerator of the whole consent workstream.
| Document / item | When needed | Why |
|---|---|---|
| Full contract archive (contracts with change‑of‑control clause) | Pre‑sale audit | Identify consent triggers |
| Contract summary table (key terms + notice periods) | Pre‑notice | Speed up triage and drafting |
| Draft consent notice and cover letter | At notice stage | Standardise requests and reduce follow‑ups |
| Authorised signatory evidence | With notice / novation | Counterparty needs proof of authority |
| Transaction documents (SPA / APA) | With consent request or negotiation | Provide context for counterparty decision |
| Regulatory filings & cover notes (FDI pack) | When notifying authorities | Required under statutory regime |
| Evidence of security / undertakings (if offered) | Negotiation stage | To obtain hard‑to‑get consents |
| Public contract documentation (award notice, clauses) | Pre‑sale audit | Determine novation constraints |
| IP assignment / licence records & registrations | Pre‑sale and notice | Show scope of rights and need for consent |
| Data processing agreements & privacy impact assessments | Pre‑notice (if data processing affected) | Review GDPR / data‑protection obligations |
| Clinical trial / marketing authorisations (life‑sciences) | Pre‑notice | Regulatory consent may be required |
| Proof of payment / fee receipts for filings | At filing | Evidence of compliance with filing requirements |
Where a counterparty is likely to resist, prepare a reinforced pack in advance: a clear transaction summary that reassures on continuity, evidence of the buyer’s financial standing, draft undertakings or guarantees, and, for IP licences, a schedule confirming the scope of licensed rights so the licensor can assess the request quickly. Anticipating objections at the drafting stage shortens the negotiation at Step 5.
The table below gives realistic durations for Spanish deals. Treat regulatory clocks as fixed and contractual windows as the variable you can compress through good drafting and early outreach. Build a buffer of at least two to three weeks over the aggregate to absorb counterparty delay.
| Step | Who owns it | Typical duration (Spain deals) |
|---|---|---|
| Contract extraction & triage | Vendor legal team (with external counsel) | 1–2 weeks |
| Prioritisation / red‑flag report | Lead counsel (buyer & seller) | 3–5 days |
| Draft and approve consent request materials | Seller + counsel | 3–7 days |
| Send notices to counterparties | Seller (or buyer if contemplated) | Day 0 |
| Counterparty response window (contractual) | Third party | 2–8 weeks (commonly 2–4 weeks) |
| Negotiation and remediation (if needed) | Deal counsel + counterparties | 1–6 weeks |
| Regulatory (FDI) notification / review | Buyer (or as required) | Several weeks to several months (statutory clock) |
| Closing & documentation of consents | Both parties | Align with agreed closing date |
| Post‑closing novation / assignment filings | Buyer / seller | 1–6 weeks post‑close |
Accelerators include a standardised consent pack, early parallel filing of regulatory notifications, a seller‑led approach to friendly counterparties, and pre‑notification meetings with regulators to smooth the FDI review. Delays typically arise from late discovery of a licence during diligence, an incomplete request pack that prompts follow‑up questions, counterparties using the consent as a renegotiation opportunity, and public contracts requiring formal administrative novation. Starting the FDI and public‑contract items first, because they run on statutory rather than commercial time, is the most reliable way to protect the overall timetable.
Budget for both professional and administrative costs, and allocate payer responsibility explicitly in the transaction documents to avoid friction later. The indicative bands below are illustrative only; obtain current fee quotations for each specific transaction.
| Cost item | Typical payer | Indicative band (EUR) | Notes |
|---|---|---|---|
| External counsel, consent audit & drafting | Seller / buyer (negotiable) | Variable, scales with scope | Scales with contract volume and complexity |
| Administrative fees for statutory filings (FDI, sector) | Usually buyer (or per rules) | As set by the relevant authority | Depends on regime and complexity |
| Government / regulator review (possible processing fees) | Buyer | Variable | Some filings are free; some require fees |
| Local counsel / translation | Buyer or seller | Variable | For local‑language notices or regulator packs |
| Notarisation / public registry fees (if required) | Buyer | As set by tariff | For certain assignments / registrations |
| Escrow / indemnity structuring costs | Buyer / seller (negotiated) | Variable | Depends on escrow agent and security |
| Administrative cost: public contract novation process | Buyer | Variable | May require formal administrative proceedings |
| Opportunity cost / delay (deal extension) | Both | Negotiation dependent | Consider break fees or contingent price adjustments |
Scope external counsel cost against contract volume early, because a high‑volume tech target with hundreds of licences will sit at the top of the band. Buyers should reserve a contingency for consent leakage, the price and term concessions counterparties may extract, and sellers should resist bearing open‑ended consent risk by capping their exposure through defined indemnity limits and survival periods.
The three principal consent routes differ in legal basis, timescale, remedies and the levers available to you. Understanding which route applies to each item dictates how you sequence and resource it.
| Issue | Contractual consent | Regulatory approval (FDI / sector) | Public contract novation |
|---|---|---|---|
| Legal basis | Private law / contract clause | Statute / administrative regime | Public procurement law (statute) |
| Typical timescale | 2–8 weeks (depends on counterparty) | Several weeks to several months (FDI can be longer) | Administrative novation / assignment; may require authority approval |
| Remedies for refusal | Remedies under contract (termination, damages) or renegotiate | Administrative appeal / change structure to avoid notification | Often requires novation or reprocurement; high risk of losing the contract |
| Practical negotiation levers | Escrows, W&I, consent undertakings | Pre‑notification meetings, mitigation undertakings | Early engagement with contracting authority; restructure (asset carve‑out) |
The dominant trend shaping change‑of‑control approvals Spain in 2026 is sustained, intensified FDI scrutiny of technology and health‑related assets, operating within the EU cooperation framework under Regulation (EU) 2019/452 and the Spanish national screening regime. Industry observers expect reviewing authorities to continue focusing on critical technologies, sensitive data and strategic capabilities, with mitigation undertakings increasingly used as a condition of clearance rather than outright prohibition.
The likely practical effect is that buyers should treat FDI assessment as a day‑one diligence item and model the statutory review clock into the critical path from the outset. Pre‑notification engagement, raising the transaction informally with the relevant authority before formal filing, can help compress timetables and surface concerns early. For life‑sciences deals, coordinate the AEMPS authorisation‑transfer analysis with the FDI assessment, since both can bear on structure. Treating change of control consents spain and regulatory screening as a single integrated workstream, rather than parallel silos, is the structural change most worth making for 2026.
Many consent failures are avoidable. They often stem from process gaps rather than genuinely unobtainable approvals.
Managing change of control consents spain well is a matter of disciplined sequencing: audit early, prioritise by deal impact, standardise your request pack, start regulatory clocks first, and allocate residual risk through clear drafting. In 2026, with FDI screening of tech and health‑related assets intensifying, the buyers and sellers who treat consents and regulatory approvals as a single integrated workstream, rather than parallel afterthoughts, are best placed to close on time and protect value. Use the checklists, timetable and templates in this guide as your operational baseline, and have a Spain‑qualified practitioner sign off on statutory references and template language before deployment.
This article was produced by Global Law Experts. For specialist advice on this topic, contact Jordi Casas at Osborne Clarke, a member of the Global Law Experts network.
posted 9 minutes ago
posted 27 minutes ago
posted 46 minutes ago
posted 1 hour ago
posted 1 hour ago
posted 1 hour ago
posted 2 hours ago
posted 2 hours ago
posted 2 hours ago
posted 2 hours ago
posted 3 hours ago
posted 3 hours ago
No results available
Find the right Legal Expert for your business
Send welcome message